The global DNases, ligases, and RNA polymerases market accounted for USD 0.804 billion in 2023 and is expected to reach USD 2.45 billion by 2034 with a CAGR of 10.66% during the forecast period 2024-2034. The market will grow due to factors such as growing emphasis on life sciences research, advancements in RNA-based therapeutics, rising demand for biopharmaceutical products, and support from institutions and the government.
The market for ligases, RNA polymerases, and DNases worldwide is driven by several reasons. These enzymes are needed for the growing biopharmaceutical industry to produce biocatalysts, purify DNA, and possibly even use gene therapy. RNA polymerases are necessary to manufacture mRNA vaccines and RNAi therapeutics, opening up a new market for growth. For instance, Almac Group said in March 2024 that the two newly constructed facilities at its headquarters in Craigavon, Northern Ireland, were complete. The peptide API synthesis as well as the commercial manufacturing and packing of sachet pharma product presentations are anticipated to increase with the opening of these new facilities.
By DNases application, the biopharmaceutical processing segment accounted for the highest revenue-grossing segment in the global DNases, ligases, and RNA polymerases market in 2023 owing to the increasing demand for biopharmaceuticals, extensive use in removing DNA contaminants, and significant investments in research and development. For instance, in January 2024, the company's selectAZyme enzyme screening collection was expanded with the introduction of an RNA Ligase (RNAL) enzyme kit by Almac Science, a part of Almac Group. Additionally, the other applications segment is predicted to grow at the fastest CAGR during the forecast period owing to the expanding use of these enzymes in emerging fields such as synthetic biology, personalized medicine, and advanced molecular diagnostics.
By ligases application, the other applications segment accounted for the highest revenue-grossing segment in the global DNases, ligases, and RNA polymerases market in 2023 owing to the increasing utilization in diverse fields such as gene therapy, molecular diagnostics, and synthetic biology, as well as significant advancements in biotechnological research. For instance, in March 2023, the University of Manchester, AstraZeneca, Novartis, and the Centre for Process Innovation Limited joined together to transform oligonucleotide synthesis. Additionally, the oligonucleotide synthesis segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for custom oligonucleotides in genetic research, advancements in gene editing technologies like CRISPR, and increasing applications in diagnostics and therapeutics.
By RNA polymerases application, the mRNA production segment accounted for the highest revenue-grossing segment in the global DNases, ligases, and RNA polymerases market in 2023 owing to the surge in demand for mRNA vaccines, especially COVID-19 vaccines, and the increasing development of mRNA-based therapeutics for various diseases. For instance, in January 2024, Almac Science, a division of the Almac Group, added an RNA Ligase (RNAL) enzyme kit to the company's selectAZyme enzyme screening library. Additionally, the others segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing application of these enzymes in innovative fields such as synthetic biology, personalized medicine, and advanced molecular diagnostics, as well as ongoing technological advancements and expanding research initiatives.
By end-user, the research and academic institutions segment accounted for the highest revenue-grossing segment in the global DNases, ligases, and RNA polymerases market in 2023 owing to the significant demand for advanced molecular biology tools and techniques for various research projects and academic studies. For instance, Illumina and Deerfield Management worked together in May 2022. The companies collaborated to select projects that had a higher chance of success utilizing genetic methods and intrinsic knowledge in order to reduce the expense of research and development and encourage the approval of innovative treatments. Additionally, the diagnostic laboratories segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of infectious diseases and the rising demand for accurate molecular diagnostics for early disease detection and management.
North American region is anticipated to have the highest revenue share during the forecast period owing to advanced healthcare infrastructure, significant investments in research and development, and a high adoption rate of molecular biology technologies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding biotechnology and pharmaceutical industries, increasing government initiatives to support scientific research, and rising investment in healthcare infrastructure. For instance, the NEBNext UltraExpress DNA and RNA library preparation kits for next-generation sequencing were introduced by New England Biolabs in November 2023.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
The market for ligases, RNA polymerases, and DNases worldwide is driven by several reasons. These enzymes are needed for the growing biopharmaceutical industry to produce biocatalysts, purify DNA, and possibly even use gene therapy. RNA polymerases are necessary to manufacture mRNA vaccines and RNAi therapeutics, opening up a new market for growth. For instance, Almac Group said in March 2024 that the two newly constructed facilities at its headquarters in Craigavon, Northern Ireland, were complete. The peptide API synthesis as well as the commercial manufacturing and packing of sachet pharma product presentations are anticipated to increase with the opening of these new facilities.
By DNases application, the biopharmaceutical processing segment accounted for the highest revenue-grossing segment in the global DNases, ligases, and RNA polymerases market in 2023 owing to the increasing demand for biopharmaceuticals, extensive use in removing DNA contaminants, and significant investments in research and development. For instance, in January 2024, the company's selectAZyme enzyme screening collection was expanded with the introduction of an RNA Ligase (RNAL) enzyme kit by Almac Science, a part of Almac Group. Additionally, the other applications segment is predicted to grow at the fastest CAGR during the forecast period owing to the expanding use of these enzymes in emerging fields such as synthetic biology, personalized medicine, and advanced molecular diagnostics.
By ligases application, the other applications segment accounted for the highest revenue-grossing segment in the global DNases, ligases, and RNA polymerases market in 2023 owing to the increasing utilization in diverse fields such as gene therapy, molecular diagnostics, and synthetic biology, as well as significant advancements in biotechnological research. For instance, in March 2023, the University of Manchester, AstraZeneca, Novartis, and the Centre for Process Innovation Limited joined together to transform oligonucleotide synthesis. Additionally, the oligonucleotide synthesis segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for custom oligonucleotides in genetic research, advancements in gene editing technologies like CRISPR, and increasing applications in diagnostics and therapeutics.
By RNA polymerases application, the mRNA production segment accounted for the highest revenue-grossing segment in the global DNases, ligases, and RNA polymerases market in 2023 owing to the surge in demand for mRNA vaccines, especially COVID-19 vaccines, and the increasing development of mRNA-based therapeutics for various diseases. For instance, in January 2024, Almac Science, a division of the Almac Group, added an RNA Ligase (RNAL) enzyme kit to the company's selectAZyme enzyme screening library. Additionally, the others segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing application of these enzymes in innovative fields such as synthetic biology, personalized medicine, and advanced molecular diagnostics, as well as ongoing technological advancements and expanding research initiatives.
By end-user, the research and academic institutions segment accounted for the highest revenue-grossing segment in the global DNases, ligases, and RNA polymerases market in 2023 owing to the significant demand for advanced molecular biology tools and techniques for various research projects and academic studies. For instance, Illumina and Deerfield Management worked together in May 2022. The companies collaborated to select projects that had a higher chance of success utilizing genetic methods and intrinsic knowledge in order to reduce the expense of research and development and encourage the approval of innovative treatments. Additionally, the diagnostic laboratories segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of infectious diseases and the rising demand for accurate molecular diagnostics for early disease detection and management.
North American region is anticipated to have the highest revenue share during the forecast period owing to advanced healthcare infrastructure, significant investments in research and development, and a high adoption rate of molecular biology technologies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding biotechnology and pharmaceutical industries, increasing government initiatives to support scientific research, and rising investment in healthcare infrastructure. For instance, the NEBNext UltraExpress DNA and RNA library preparation kits for next-generation sequencing were introduced by New England Biolabs in November 2023.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by DNases Application, Ligases Application, RNA Polymerases Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement
Segmentation: DNases, Ligases, And RNA Polymerases Market Report 2023 - 2034
DNases, Ligases, And RNA Polymerases Market Analysis & Forecast by DNases Application 2023 - 2034 (Revenue USD Bn)
- Biopharmaceutical Processing
- Other Applications
DNases, Ligases, And RNA Polymerases Market Analysis & Forecast by Ligases Application 2023 - 2034 (Revenue USD Bn)
- Oligonucleotide Synthesis
- Other Applications
DNases, Ligases, And RNA Polymerases Market Analysis & Forecast by RNA Polymerases Application 2023 - 2034 (Revenue USD Bn)
- mRNA Production
- Other Applications
DNases, Ligases, And RNA Polymerases Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Biopharmaceutical Processing
- Research and Academic Institutions
- Diagnostic Laboratories
- Pharmaceutical Companies
DNases, Ligases, And RNA Polymerases Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. DNases, Ligases, And RNA Polymerases Market: DNases Application Estimates & Trend Analysis
8. DNases, Ligases, And RNA Polymerases Market: Ligases Application Estimates & Trend Analysis
9. DNases, Ligases, And RNA Polymerases Market: RNA Polymerases Application Estimates & Trend Analysis
10. DNases, Ligases, And RNA Polymerases Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America DNases, Ligases, And RNA Polymerases Market
13. Europe Global DNases, Ligases, And RNA Polymerases Market
14. Asia Pacific Global DNases, Ligases, And RNA Polymerases Market
15. Latin America Global DNases, Ligases, And RNA Polymerases Market
16. MEA Global DNases, Ligases, And RNA Polymerases Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Thermo Fisher Scientific Inc.
- New England Biolabs
- Merck KGaA
- Promega Corporation
- Agilent Technologies
- QIAGEN
- Takara Bio Inc.
- Illumina Inc.
- Roche Holding AG
- Bio-Rad Laboratories Inc.
- Enzymatics Inc.
- GenScript Biotech Corporation
- Lonza Group Ltd.
- OriGene Technologies Inc.
- Becton
- Dickinson and Company (BD)
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | October 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 0.8 Billion |
| Forecasted Market Value ( USD | $ 2.45 Billion |
| Compound Annual Growth Rate | 10.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
